Deep Value: cash covers more than 100% of the stock price

This company holds roughly $3M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Oxford BioDynamics

OBD.L

Biotechnology · Healthcare

Price

0.11 GBp

+0.01 (+4.76%)

Market Cap

2.3M GBp

Exchange

London Stock Exchange

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 9, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+1398.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 92.6M (2021) → 1.39B (2025)

Oxford BioDynamics is a small UK-based biotechnology company that develops blood tests to help doctors make better decisions about treating patients. Its main technology, called EpiSwitch, analyzes patterns in a person's DNA to detect diseases and predict how patients will respond to certain treatments. The company focuses on areas like cancer and immune disorders, working with pharmaceutical companies and healthcare researchers as its primary customers.

Oxford BioDynamics earns revenue mainly through licensing its EpiSwitch technology to pharmaceutical partners and providing testing services, though it currently spends far more than it earns. It operates primarily in the UK and the US, and its competitive position rests on its proprietary platform for reading specific DNA structures called chromatin. The company's deeply negative margins reflect its early-stage nature, and its main challenge is proving that its tests are clinically useful enough to win broader adoption and secure the partnerships needed to reach profitability.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+17.0% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+82.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$615,000/ year

↓ Declining (-24% vs prior year)

56.2% of revenue

3.1x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

35.0%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$3M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Oxford BioDynamics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-35.2%

Thin — -35.2% gross margin

Operating Margin

-686.3%

Losing money on operations — -686.3%

ROCE

-113.5%

Weak — -113.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+33.4%

Fast-growing sales (+33.4% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-610.8%

Burning cash (-610.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.28

Conservative — low debt load (0.28)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial